Roche Completes Acquisition of TIB Molbiol Group
|
By LabMedica International staff writers Posted on 02 Dec 2021 |

Roche (Basel, Switzerland) has completed its share purchase agreement to acquire 100% of the outstanding shares of TIB Molbiol Group (Berlin, Germany).
TIB Molbiol will continue to operate as a subsidiary within the Diagnostics division. Roche and TIB Molbiol will build on their capabilities for the rapid development of assays for emerging pathogens and potential health threats, such as infectious diseases. The two companies have collaborated for more than 20 years to rapidly address critical healthcare needs including biological threats, such as SARS, anthrax, avian influenza virus H5N1, MERS, the novel influenza virus H1N1 swine, Ebola virus, Zika virus and most recently, SARS-CoV-2 virus and its variants. For example, in 2001 with anthrax and 2003 with SARS-CoV1, TIB Molbiol demonstrated their ability to develop PCR assays for the detection of new pathogens within days.
With over 45 CE-IVD assays and more than a 100 research-use-only assays joining the Roche family, the companies will jointly accelerate access for patients around the world to even more clinically important diagnostic tests. TIB Molbiol will further expand Roche’s molecular diagnostics solutions, especially for the flexible open platforms LightCycler PCR and MagNA Pure sample preparation systems.
“I am very pleased that together with TIB Molbiol, we can significantly improve access for patients to a broader spectrum of diagnostic tests - from high volume routine tests to the diagnosis of rare diseases. TIB Molbiol will continue to be an innovation engine and frontrunner in our common fight against infectious diseases, such as SARS-CoV-2,” said Thomas Schinecker, CEO Roche Diagnostics. “TIB Molbiol has helped to shape the future of PCR infectious disease testing, and will continue to drive cutting-edge research so we can bring better healthcare outcomes to patients faster.”
Related Links:
Roche
TIB Molbiol
Latest Industry News
- Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry
- Health Canada Licenses Point-of-Care Hematology Analyzer for Decentralized CBC Testing
- New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
- Fujirebio Expands Access to Automated Blood-Based Neurology Testing in Canada
- Natera ctDNA Test to Support Response Monitoring in Solid Tumor Trial
- Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring
- Companion Diagnostics Expand HER2 Testing in Metastatic Gastroesophageal Cancer
- Global Urinalysis Market Gowth Driven by Demand for Automated and POC Testing
- New Collaboration Expands Point-of-Care Testing Across UK Community Pharmacies
- New Collaboration Advances Precision Oncology Screening for Lung Cancer in Japan
- AI-Powered Pathology Collaboration Supports Companion Diagnostic Development
- Strategic Collaboration Expands Commercial Access to Oncology Companion Diagnostics
- Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
- Standardized Staining Technology Advances Digital Pathology Workflows
- Global Testing Service Advances Leukemia MRD Monitoring
- Ultrasensitive MRD Assay Gains Medicare Coverage for Immunotherapy and Breast Cancer Monitoring
Channels
Clinical Chemistry
view channel
International Consensus Guidance Outlines General Population Screening for Early-Stage Type 1 Diabetes
Type 1 diabetes (T1D) is an autoimmune disease that can develop in childhood or adulthood and affects an estimated 9.5 million people worldwide. Its complications range from acute diabetic ketoacidosis... Read more
Algorithm Uses Blood Biomarkers to Improve Alzheimer’s Trial Screening
Alzheimer’s disease is a progressive neurodegenerative disorder that causes memory loss and functional decline. Screening cognitively healthy adults for prevention trials is slow and costly because many... Read moreMolecular Diagnostics
view channel
Blood Protein Analysis Helps Interpret Uncertain Rare Disease Variants
Many patients with suspected rare genetic conditions remain undiagnosed even after genome or exome sequencing, leaving clinicians with limited evidence to interpret uncertain variants. Variants of uncertain... Read more
40-Gene Test Validated for High-Risk Squamous Cell Carcinoma
High-risk cutaneous squamous cell carcinoma (SCC) requires accurate stratification to align surveillance and adjuvant therapy with each patient’s risk. Clinicopathologic staging alone may not precisely... Read moreHematology
view channel
Borderline Anemia May Carry Higher Risk Than Current Thresholds Suggest
Hemoglobin concentration is among the most frequently ordered blood tests in primary and hospital care. In older adults, both high and low values have been linked to adverse outcomes, including cognitive... Read more
Biomarker-Guided Framework Aims to Guide Mantle Cell Lymphoma Therapy
Mantle cell lymphoma can follow widely variable courses, from indolent disease to rapidly progressive cancer, complicating initial treatment selection. Many therapeutic decisions still rely on patient... Read moreImmunology
view channel
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read moreMicrobiology
view channel
Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read more
Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read morePathology
view channel
AI Spatial Analysis of Routine Slides Helps Predict Pancreatic Cancer Recurrence
Predicting which patients with pancreatic cancer will recur after treatment and surgery remains challenging. Pathology evaluation typically measures residual tumor burden, but recent work found that tumor... Read more
Hybrid Computational Imaging Method Improves Digital Pathology Resolution
Digital pathology depends on high-resolution whole-slide imaging to capture diagnostically relevant cellular and tissue features, yet conventional methods often force trade-offs between speed, cost, and detail.... Read moreTechnology
view channel
New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more







